ecteinascidin 743 has been researched along with camptothecin in 14 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | ecteinascidin 743 (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL | 1 |
| Carrassa, L; D'Incalci, M; Damia, G; Faircloth, GT; Filiberti, L; Foiani, M; Liberi, G; Silvestri, S | 1 |
| Patel, SR | 1 |
| Banerjee, D; Bertino, JR; Brennan, MF; Chou, TC; Guan, Y; Li, W; Scotto, KW; Takahashi, N; Wada-Takahashi, Y | 1 |
| D'Incalci, M; Faircloth, GT; Jimeno, J; Marabese, M; Mazzarella, G; Meco, D; Riccardi, A; Riccardi, R; Ubezio, P | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Grohar, PJ; Helman, LJ | 1 |
| D'Incalci, M; Grohar, PJ; Helman, LJ; Mendoza, A; Pommier, Y; Segars, LE; Yeung, C | 1 |
| Burdach, S | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Burdach, S; D'Incalci, M; DaPrada, GA; Fregoni, V; Grohar, PJ; Pavesi, L; Riccardi, A; Tancredi, R; Zambelli, A | 1 |
| Allonca, E; Astudillo, A; Fernandez-Garcia, MT; Garcia-Pedrero, JM; Martinez-Cruzado, L; Rodriguez, A; Rodriguez, R; Santos, L; Tornin, J | 1 |
| Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G | 1 |
3 review(s) available for ecteinascidin 743 and camptothecin
| Article | Year |
|---|---|
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Prospects and challenges for the development of new therapies for Ewing sarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Camptothecin; Clinical Trials as Topic; Dioxoles; Epigenesis, Genetic; Humans; Molecular Targeted Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Somatomedins; Tetrahydroisoquinolines; Trabectedin | 2013 |
11 other study(ies) available for ecteinascidin 743 and camptothecin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 1999 |
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Topics: Androstadienes; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Camptothecin; Cell Survival; CHO Cells; Cricetinae; Dioxoles; DNA; DNA Repair; DNA Topoisomerases, Type I; DNA-Activated Protein Kinase; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Isoquinolines; Nuclear Proteins; Protein Serine-Threonine Kinases; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Wortmannin | 2001 |
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; Cisplatin; Dioxoles; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Isoquinolines; Mice; Mice, Nude; Mitosis; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dioxoles; DNA Topoisomerases, Type I; Humans; In Vitro Techniques; Irinotecan; Isoquinolines; Male; Mice; Mice, Nude; Rhabdomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dioxoles; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Irinotecan; Mice; Oncogene Proteins, Fusion; Phenotype; Proto-Oncogene Protein c-fli-1; RecQ Helicases; RNA Interference; RNA-Binding Protein EWS; RNA, Small Interfering; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Werner Syndrome Helicase; Xenograft Model Antitumor Assays | 2014 |
Molecular precision chemotherapy: overcoming resistance to targeted therapies?
Topics: Animals; Antineoplastic Agents; Camptothecin; Dioxoles; DNA Damage; Female; Humans; Irinotecan; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin | 2014 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
Topics: Adult; Camptothecin; Dioxoles; Humans; Irinotecan; Male; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin | 2015 |
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Dioxoles; DNA Damage; Drug Synergism; Humans; Liposarcoma; Liposarcoma, Myxoid; Mice; Neoplastic Stem Cells; Signal Transduction; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neoplasms; Fluorouracil; Green Fluorescent Proteins; Humans; Leucovorin; Mice; Mice, Nude; Mice, Transgenic; Random Allocation; Trabectedin; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |